

SINGAPORE ROUNDUP

R&D centre for cancer treatments set up

THE National Cancer Centre Singapore (NCCS) and Clearbridge BioMedics have partnered the Singapore General Hospital (SGH) to set up the region's first Circulating Tumour Cell Centre of Research Excellence. The centre will be a key enabler in Singapore's efforts to advance the development of personalised medicine.

The research being conducted there will seek to understand the genetic make-up of a patient's cancer cells, which can evolve over time. It will focus on a number of research programmes and clinical trials at NCCS and SGH, including the pilot use of Clearbridge BioMedics' ClearCell FX system, an enrichment system for circulating tumour cells.